← Leaderboards
Walter T Ambrosius
Indiana Univ-Purdue Univ At Indianapolis
$5,507,928
Attributed
$8,265,868
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $18.6M · FY2015–25$20M$15M$10M$5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$92,255,420 · 5
By mechanism
U19$83,989,552 · 1
U01$5,515,881 · 1
U24$2,176,587 · 2
P30$573,400 · 1
Top collaborators
- Karen P Alexander6 shared
- Adrian Hernandez6 shared
- Jeff Douglas Williamson6 shared
- Marco Pahor4 shared
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Daniel O Clark$10,012,974
- Johnny J He$17,169,604
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsPreventParticipantSuccessSafetyElderlyReportingMuscleMedical SchoolsInternationalLeadMethodologyRecruitEvaluationFundingPharmaceutical PreparationsPrimary OutcomeUnited States National Institutes Of HealthData ManagementAlzheimer&AposDesignDiabetes MellitusMonitorBlood Pressure Intervention
Grant awards (22)
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$10,487,354
U19 · FY2025 · AG
2/2 Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial$618,504
U24 · FY2025 · HL · contact PI
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC$200,993
U24 · FY2025 · HL · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$13,319,036
U19 · FY2024 · AG
2/2 Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial$699,396
U24 · FY2024 · HL · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$15,644,347
U19 · FY2023 · AG
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC$108,792
U24 · FY2023 · HL · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$18,482,472
U19 · FY2022 · AG
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC$95,815
U24 · FY2022 · HL · contact PI
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC$97,162
U24 · FY2021 · HL · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$15,392,504
U19 · FY2020 · AG
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC$134,540
U24 · FY2020 · HL · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$10,663,839
U19 · FY2019 · AG
2/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC$221,385
U24 · FY2019 · HL · contact PI
The ENRGISE Study$1,355,307
U01 · FY2017 · AG
The ENRGISE Study$2,201,275
U01 · FY2016 · AG
The ENRGISE Study$99,786
U01 · FY2016 · AG
The ENRGISE Study$1,859,513
U01 · FY2015 · AG
Core--Biostatistics Support$143,350
P30 · FY2002 · NR
Core--Biostatistics Support$143,350
P30 · FY2001 · NR
Core--Biostatistics Support$143,350
P30 · FY2000 · NR
Core--Biostatistics Support$143,350
P30 · FY2000 · NR